NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Tags: immunotherapy


Reuters story on kidney cancer drug makes us ask: How is this journalism?


Immunotherapy prolongs survival, but at what cost? Washington Post needed more on treatment downsides


Without any independent sources providing insight, readers of TIME’s coverage on lung cancer immunotherapy mostly left in the dark


Washington Post wisely quantifies severe side effects and deaths from CAR-T cell therapy


AP’s story on cancer immunotherapy quickly mentions low success rate


Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000


It’s misleading to call results from phase 1 trials with 6 and 13 patients a ‘cancer breakthrough’


Immunotherapy’s ‘new era:’ LA Times story overlooks the risks and overstates trial results


Keytruda for bladder cancer: No independent scrutiny of Merck-reported results


‘Promising’ new lymphoma treatment gets superficial, one-sided coverage by CBS